Logotype for Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals (MRNS) investor relations material

Marinus Pharmaceuticals Investor Presentation summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Marinus Pharmaceuticals Inc
Investor Presentation summary12 Nov, 2024

Product and clinical overview

  • Ganaxolone is a neuroactive steroid that modulates both synaptic and extrasynaptic GABA receptors, offering a differentiated mechanism of action for epilepsy treatment.

  • ZTALMY (ganaxolone) is FDA-approved for CDKL5 deficiency disorder (CDD) and has a well-characterized safety profile, addressing a significant unmet need.

  • In the Phase 3 Marigold trial, ganaxolone reduced major motor seizure frequency by a median of 30.7% versus 6.9% for placebo; sustained reductions of ~50% were observed over two years in the open-label extension.

  • The most frequent adverse events were somnolence, pyrexia, and upper respiratory tract infection, with safety findings consistent across studies.

Commercial performance and strategy

  • Net product revenue for ZTALMY reached $8.5M in Q3 2024, a 56% increase from Q3 2023, with full-year revenue expected at $33–34M.

  • Achieved profitability on ZTALMY commercial investment in Q1 2024, ahead of target, driven by strong patient enrollments and prescriber growth.

  • Commercial strategy includes focused education for healthcare providers, enhanced patient support, and increased investment in patient identification.

  • Global access is expanding through partnerships in Europe (Orion), China (Tenacia), MENA (Biologix), and a distribution agreement with Uniphar Group.

Clinical pipeline and trial results

  • In the Phase 3 TrustTSC trial for TSC-associated seizures, ganaxolone showed a 19.7% reduction in seizure frequency versus 10.2% for placebo; the primary endpoint was not statistically significant (p=0.0904).

  • The RAISE Phase 3 trial in refractory status epilepticus (SE) showed IV ganaxolone led to SE cessation within 30 minutes in 80% of patients versus 13% for placebo (p<0.0001), with similar rates of serious adverse events.

  • Median time to SE cessation was 4.2 minutes for IV ganaxolone versus 307.2 minutes for placebo; EEG seizure burden reduction was 93% for ganaxolone versus 36% for placebo (p=0.003).

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy with a focus on rare and orphan seizures, as well as neuropsychiatric disorders in the United States.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage